Lei Jiang

Title: Lei Jiang: Innovator in mRNA Therapy for Acute Intermittent Porphyria

Introduction

Lei Jiang is a prominent inventor based in Cambridge, MA, specializing in mRNA therapies. She has made significant contributions to the field of genetic medicine, particularly in the treatment of rare diseases. Her innovative approach focuses on utilizing mRNA to address deficiencies in enzyme activity.

Latest Patents

Lei Jiang holds a patent for "Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria." This invention relates to mRNA therapy aimed at treating Acute Intermittent Porphyria (AIP). The mRNAs developed in this invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD) and its functional fragments. These mRNAs are preferably encapsulated in lipid nanoparticles (LNPs) to ensure efficient delivery to cells and tissues. The therapy aims to increase and restore deficient levels of PBGD expression and activity, thereby reducing toxic metabolites associated with AIP.

Career Highlights

Throughout her career, Lei Jiang has worked with notable organizations, including ModernaTX, Inc. and Fundación Para La Investigación Médica Aplicada. Her work has been instrumental in advancing the understanding and treatment of genetic disorders through innovative therapeutic strategies.

Collaborations

Lei Jiang has collaborated with esteemed colleagues such as Paolo Martini and Stephen G. Hoge. These partnerships have further enhanced her research and development efforts in the field of mRNA therapy.

Conclusion

Lei Jiang's contributions to mRNA therapy represent a significant advancement in the treatment of Acute Intermittent Porphyria. Her innovative work continues to pave the way for new therapeutic options in genetic medicine.